Elanco Director Purchases 40,000 Shares for $936,000
Purchasing 40,000 shares is a bullish signal for shareholders.
Elanco Animal Health's Director, Lawrence Erik Kurzius, acquired 40,000 shares of the company's common stock on August 20, 2026, according to a recently filed SEC Form 4 document. Kurzius paid a weighted average of $23.40 per share, with a post-transaction market value of $23.56 per share. Elanco, a leading global animal health company, employs around 9,400 people and generated $5 billion in revenue for the trailing twelve months, showcasing its significant presence in the pharmaceutical and animal health sector.
The company's business model is diverse, encompassing companion animal preventive care, therapeutic treatments, and livestock health solutions, allowing it to generate income from various customer segments and regions. Elanco's competitive edge is bolstered by its extensive portfolio of well-known brands and comprehensive product range, which effectively tackle essential animal health requirements across both companion and production animal markets.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
